stockrow
Friday 6 November 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
69.55
0.84
+1.22%
Follow EXEL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
16.88 | 16.49 | 13.70 | 15.17 |
+8 more quarters Free account |
P/S ratio |
5.77 | 5.60 | 4.66 | 5.13 | |
P/FCF ratio |
12.59 | 11.78 | 12.24 | 14.10 | |
P/Operating CF |
51.48 | 44.34 | 43.99 | 35.69 | |
P/B ratio |
7.86 | 7.40 | 5.72 | 5.51 | |
Price to Tangible BV |
8.14 | 7.67 | 5.92 | 5.67 | |
EV/Sales |
5.42 | 5.27 | 4.35 | 4.68 | |
EV/EBITDA |
13.13 | 12.83 | 10.70 | 12.06 | |
EV/Operating CF |
11.55 | 10.84 | 11.17 | 12.29 | |
EV/FCF |
11.83 | 11.08 | 11.41 | 12.87 | |
Quick Ratio |
2.96 | 3.21 | 2.98 | 3.32 | |
Current Ratio |
3.21 | 3.46 | 3.26 | 3.56 | |
Net Debt/EBITDA |
(3.24) | (3.29) | (3.01) | (4.37) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.94 | 0.94 | 0.87 | 0.80 | |
Operating CF/Net income |
1.28 | 1.45 | 1.20 | 1.36 | |
Capex/Depreciation |
(1.45) | (1.33) | (0.29) | (1.03) | |
Research and Development Expense of Revenue |
31.80% | 33.72% | 32.73% | 35.62% | |
Selling, General and Administrative Expense of Revenue |
23.46% | 23.48% | 22.86% | 20.55% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
4.36% | 5.18% | 4.76% | 3.36% | |
Graham Net Nets |
0.04 | 0.04 | 0.05 | 0.06 | |
Graham Number |
24.05 | 23.36 | 22.97 | 22.75 | |
Earnings Yield |
5.92% | 6.07% | 7.30% | 6.59% | |
Free Cash Flow Yield |
7.94% | 8.49% | 8.17% | 7.09% | |
Revenue per Share |
2.67 | 2.51 | 2.36 | 2.20 | |
Operating CF per Share |
1.13 | 1.23 | 0.97 | 1.23 | |
Capex per Share |
(0.04) | (0.04) | (0.01) | (0.03) | |
Free Cash Flow per Share |
1.09 | 1.19 | 0.97 | 1.20 | |
Cash per Share |
3.62 | 3.35 | 3.01 | 3.90 | |
Shareholders Equity per Share |
7.43 | 7.35 | 7.49 | 7.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.43 | 7.35 | 7.49 | 7.96 | |
Free Cash Flow |
269.89 | 298.43 | 249.81 | 326.36 | |
Working Capital |
909.75 | 888.90 | 837.66 | 1,037.65 | |
Capital Expenditures |
(10.06) | (9.32) | (2.03) | (7.16) | |
Net Current Asset Value |
641.97 | 600.35 | 550.79 | 760.19 | |
EV/EBIT |
13.50 | 13.21 | 11.02 | 12.46 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
14.36 | 14.05 | 11.83 | 13.65 | |
| Other line items | |||||
Average Receivables |
319.10 | 307.28 | 305.29 | 276.18 | |
Average Payables |
28.09 | 32.44 | 33.50 | 33.91 | |
Average Inventory |
28.64 | 26.11 | 25.73 | 22.04 | |
Average Assets |
2,668.52 | 2,586.16 | 2,715.42 | 2,896.06 | |
Average Common Equity |
1,997.27 | 1,938.65 | 2,033.39 | 2,202.76 |
Columns are period end dates · fundamentals updated 5 Nov 2026